tradmap

ABOS Acumen Pharmaceuticals, Inc.

$3.09 -0.64%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Acumen Pharmaceuticals, Inc. (ABOS) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $223 million. Shares last traded at $3.09, 29.0% below their 52-week high. Over the past year the stock is up 124.7%. Net profit margin is -973.4%, below the peer median of 5.3%.

Market Cap
$223M
Shares Out
72.3M
EPS (TTM)
$-3.86
P/E Ratio
P/S Ratio
20.71
P/B Ratio
3.90
Dividend / Share
Dividend Yield
52-Week High
$4.35
52-Week Low
$1.21
Volume
31,753
Avg Vol (3m)
22,534.397

Performance

1W
+1.98%
1M
+37.95%
3M
+35.23%
6M
-7.35%
YTD
+52.97%
1Y
+124.73%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
64.82
SMA (50)
$2.57
SMA (200)
$2.44
Price vs SMA50
+20.33%
Price vs SMA200
+26.73%
ATR (14)
$0.16

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$11M
Net Income
$-105M
Gross Margin
Operating Margin
-976.9%
Net Margin
-973.4%
Return on Equity
-183.4%
Return on Assets
-90.5%
Current Ratio
2.47
Debt / Equity
0.21
Revenue Growth (YoY)

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.79 2026-08-12
Q1 2026 $-0.33 2026-05-12
FY 2025 $-2.00 2026-03-26
Q3 2025 $-1.59 2025-11-12
Q2 2026 $-1.15 2026-08-12
Q1 2026 $-0.48 2026-05-12

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

ABOS vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
20.71 / 19.49 med
+6% premium
Net margin vs peers
-973.4% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.